Grant: Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Université Laval
$100,000.00
Validating and refining genome-wide signals for genetic determinants of bone mineral density in pre and post-menopausal women.
FY 2011-12
Summary
Osteoporosis is a common disease affecting a majority of old women. It is characterized by low bone mass, architectural deterioration of bone and an increased risk of fractures. Bone density is determined more strongly by a person's genetic background than by life habits and environment. However, few gene variants have been associated with bone density with high confidence. Recently, studies looked at the whole genome in relation to bone density. These studies revealed several new potential genes for low bone density but these need to be validated in independent samples. Furthermore, some genes might be important for peak bone mass while others might be important for the rate of bone loss observed during menopausal transition. Within these potential genes, the true DNA variant causing these effects need to be indentified. We have collected a large number of women of different (pre and post) menopausal status to help define the role of these putative gene variants. Validated genetic markers involved in peak bone mass may serve to identify young women at risk of low peak bone mass and who could benefit of preventive measures to help reaching optimal peak bone mass. Markers involved in bone loss could identify women who will benefit most from antiresorptive treatment at the time of menopause. It may thus become possible to identify individuals with a higher susceptibility to low bone density and establish, in early adulthood, focused (or even tailored) preventive programs to minimize their risk of bone fracture later in their life. Such a strategy using validated genetic markers of future low bone density may allow to diminish the burden of this disease, that will undoubtedly increase further in the future due to population ageing.
Department
Program
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
250112
Name
Rousseau François
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Genetics
Projecttitle
Validating and refining genome-wide signals for genetic determinants of bone mineral density in pre and post-menopausal women.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Keyworddelim
Bone Metabolism; Human Genetics; Laboratory Medicine; Osteoporosis; Peak Bone Mass; Translational Research
Abstract
Osteoporosis is a common disease affecting a majority of old women. It is characterized by low bone mass, architectural deterioration of bone and an increased risk of fractures. Bone density is determined more strongly by a person's genetic background than by life habits and environment. However, few gene variants have been associated with bone density with high confidence. Recently, studies looked at the whole genome in relation to bone density. These studies revealed several new potential genes for low bone density but these need to be validated in independent samples. Furthermore, some genes might be important for peak bone mass while others might be important for the rate of bone loss observed during menopausal transition. Within these potential genes, the true DNA variant causing these effects need to be indentified. We have collected a large number of women of different (pre and post) menopausal status to help define the role of these putative gene variants. Validated genetic markers involved in peak bone mass may serve to identify young women at risk of low peak bone mass and who could benefit of preventive measures to help reaching optimal peak bone mass. Markers involved in bone loss could identify women who will benefit most from antiresorptive treatment at the time of menopause. It may thus become possible to identify individuals with a higher susceptibility to low bone density and establish, in early adulthood, focused (or even tailored) preventive programs to minimize their risk of bone fracture later in their life. Such a strategy using validated genetic markers of future low bone density may allow to diminish the burden of this disease, that will undoubtedly increase further in the future due to population ageing.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rousseau, François
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~